Wockhardt Obtains US FDA Nod For Generic Version Of Aricept Tablets

Pharmaceutical and biotechnology major Wockhardt Ltd. has received tentative approval from the US FDA for marketing 5mg and 10mg tablets of Donepezil HCl, which is used for treatment of Alzheimer's disease and dementia.

Donepezil is the generic name for the brand Aricept, marketed in the US by Eisai in partnership with Pfizer. The company would be launching the product in the US market on May 28 this year.

According to IMS Health data, the total market for this product in the US is around $2.5 billion.

Donepezil is amongst the most widely used drugs in treating Alzheimer's disease, incidences of which are rapidly increasing the world over due to a steady increase in aging population.

At the BSE, Wockhardt shares are being traded at Rs.361, up by 2.47 percent from the previous close.

For comments and feedback contact: editorial@rttnews.com

Follow RTT